• Explore /
  • Poster
  • / Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.

Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.

Abstract Poster

Authors

Daniel Castellano

Daniel E. Castellano

Hospital Universitario 12 de Octubre, Madrid, Spain

Daniel E. Castellano , Ignacio Duran , Begona Mellado , Miguel Angel A. Climent Duran , Xavier Garcia del Muro , Nuria Sala González , Teresa Alonso Gordoa , Elena Sevillano , Montserrat Domenech , Jesus Paramio , Francisco X. Real , Nuria Malats , Juan Luis Sanz , Albert Font

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03425201

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 490)

DOI

10.1200/JCO.2022.40.6_suppl.490

Abstract #

490

Poster Bd #

E9

Abstract Disclosures

Similar Posters

First Author: Albert Font Pous

First Author: Daniel E. Castellano

First Author: Abhishek Tripathi

First Author: Jessica Dreger McDermott